235 related articles for article (PubMed ID: 26443019)
21. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
22. Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial.
Forrester DL; Knox AJ; Smyth AR; Barr HL; Simms R; Pacey SJ; Pavord ID; Honeybourne D; Dewar J; Clayton A; Fogarty AW
Pediatr Pulmonol; 2016 Mar; 51(3):253-7. PubMed ID: 26709241
[TBL] [Abstract][Full Text] [Related]
23. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
Tramper-Stranders GA; Wolfs TF; van Haren Noman S; van Aalderen WM; Nagelkerke AF; Nuijsink M; Kimpen JL; van der Ent CK
Thorax; 2010 Oct; 65(10):915-20. PubMed ID: 20729233
[TBL] [Abstract][Full Text] [Related]
24. Rhinovirus-associated pulmonary exacerbations show a lack of FEV1 improvement in children with cystic fibrosis.
Cousin M; Molinari N; Foulongne V; Caimmi D; Vachier I; Abely M; Chiron R
Influenza Other Respir Viruses; 2016 Mar; 10(2):109-12. PubMed ID: 26493783
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal analysis of FEV1 changes related to antibiotic therapy in children with cystic fibrosis.
Javadpour S; Jones A; Brownlee K
Ir Med J; 2007; 100(7):529-32. PubMed ID: 17886526
[TBL] [Abstract][Full Text] [Related]
26. Lactobacillus reuteri ATCC55730 in cystic fibrosis.
Di Nardo G; Oliva S; Menichella A; Pistelli R; De Biase RV; Patriarchi F; Cucchiara S; Stronati L
J Pediatr Gastroenterol Nutr; 2014 Jan; 58(1):81-6. PubMed ID: 24121143
[TBL] [Abstract][Full Text] [Related]
27. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.
Pamukcu A; Bush A; Buchdahl R
Pediatr Pulmonol; 1995 Jan; 19(1):10-5. PubMed ID: 7675552
[TBL] [Abstract][Full Text] [Related]
28. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
[TBL] [Abstract][Full Text] [Related]
29. Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum.
Baxter CG; Rautemaa R; Jones AM; Webb AK; Bull M; Mahenthiralingam E; Denning DW
Thorax; 2013 Jul; 68(7):652-7. PubMed ID: 23513028
[TBL] [Abstract][Full Text] [Related]
30. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection.
Bisgaard H; Pedersen SS; Nielsen KG; Skov M; Laursen EM; Kronborg G; Reimert CM; Høiby N; Koch C
Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1190-6. PubMed ID: 9351621
[TBL] [Abstract][Full Text] [Related]
31. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
[TBL] [Abstract][Full Text] [Related]
32. Vitamin D status correlates with the markers of cystic fibrosis-related pulmonary disease.
Wani WA; Nazir M; Bhat JI; Malik EU; Ahmad QI; Charoo BA; Ali SW
Pediatr Neonatol; 2019 Apr; 60(2):210-215. PubMed ID: 30093293
[TBL] [Abstract][Full Text] [Related]
33. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
Pirzada OM; McGaw J; Taylor CJ; Everard ML
J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
[TBL] [Abstract][Full Text] [Related]
34. Effect of high-dose ibuprofen in patients with cystic fibrosis.
Konstan MW; Byard PJ; Hoppel CL; Davis PB
N Engl J Med; 1995 Mar; 332(13):848-54. PubMed ID: 7503838
[TBL] [Abstract][Full Text] [Related]
35. Paranasal sinus pathogens in children with cystic fibrosis: do they relate to lower respiratory tract pathogens and is eradication successful?
Wilson P; Lambert C; Carr SB; Pao C
J Cyst Fibros; 2014 Jul; 13(4):449-54. PubMed ID: 24713592
[TBL] [Abstract][Full Text] [Related]
36. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
[TBL] [Abstract][Full Text] [Related]
37. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis.
Smith AL; Redding G; Doershuk C; Goldmann D; Gore E; Hilman B; Marks M; Moss R; Ramsey B; Rubio T
J Pediatr; 1988 Apr; 112(4):547-54. PubMed ID: 3127569
[TBL] [Abstract][Full Text] [Related]
38. Effect of supplementary zinc on body mass index, pulmonary function and hospitalization in children with cystic fibrosis.
Ataee P; Najafi M; Gharagozlou M; Aflatounian M; Mahmoudi M; Khodadad A; Farahmand F; Motamed F; Fallahi GH; Kalantari N; Soheili H; Modarresi V; Modarresi MS; Rezaei N
Turk J Pediatr; 2014; 56(2):127-32. PubMed ID: 24911844
[TBL] [Abstract][Full Text] [Related]
39. Edetate sodium aerosol in Pseudomonas lung infection in cystic fibrosis.
Brown J; Mellis CM; Wood RE
Am J Dis Child; 1985 Aug; 139(8):836-9. PubMed ID: 3927708
[TBL] [Abstract][Full Text] [Related]
40. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis.
Van Wye JE; Collins MS; Baylor M; Pennington JE; Hsu YP; Sampanvejsopa V; Moss RB
Pediatr Pulmonol; 1990; 9(1):7-18. PubMed ID: 1697059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
